New Medicaid Pricing Model: Financial Impacts and Future of Drug Costs
Discover how the new Medicaid pricing model aims to reduce drug costs and its potential impact on the insurance industry and healthcare savings.
Dr. Mehmet Oz Predicts Healthcare Cost Surges Despite Drug Price Reductions
Dr. Mehmet Oz warns of rising healthcare costs by 2027 despite recent drug price cuts, highlighting Medicare negotiations and affordability initiatives.
The Role and Impact of Pharmacy Benefit Managers on Healthcare Costs
Explore how pharmacy benefit managers influence drug pricing and healthcare access. Understand their role in mail orders and emerging legislative actions.
Maryland’s Groundbreaking Law on Medicare Prescription Drug Savings
Understand Maryland's new law extending Medicare drug savings, its impact on insurance pricing, and the need for regulatory compliance adjustments.
Impact of MFN Pricing on Medicare's Drug Spending for Obesity Treatments
Explore how MFN pricing for GLP-1RAs impacts Medicare spending and beneficiaries, while addressing obesity treatment affordability and regulatory challenges.
Medicare GLP-1 Bridge Program: A Paradigm Shift in Drug Pricing
Explore the CMS Medicare GLP-1 Bridge program revolutionizing drug pricing for Medicare beneficiaries with a fixed $50 monthly cost.
Impact of CMS Proposal on Drug Price Negotiations and Innovation
Explore the CMS proposal's impact on drug pricing negotiations, innovation, and pharmaceutical investment strategies in this crucial healthcare policy update.
New CMS Guidance on Medicare Drug Pricing Initiatives
Discover CMS's draft guidance on Medicare drug pricing, impacting stakeholders and beneficiaries, designed to streamline processes and enhance compliance.
Proposed Changes to Medicare Payment Systems for 2027
Explore the proposed 2027 Medicare payment system changes, affecting outpatient services, drug pricing, and quality reporting. Learn about key impacts for providers.
Phil Perry Retires: Impact on 340B Program Litigation and Regulation
Phil Perry's retirement signals notable changes in 340B litigation as CMS proposes a new rule impacting drug payments; public comment open through August 2026.